IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the nomination committee has provided their proposal and motivated opinion ahead of the annual general meeting 2021. Martin Nicklasson is proposed as a new board member. Martin Nicklasson has extensive experience from the international pharmaceutical industry, primarily from executive positions within AstraZeneca, Pharmacia, Biovitrum and Sobi as well as a board member in several life science companies.
In addition to the nomination of Martin Nicklasson as a board member, the nomination committee proposes re-election of Gunnar Olsson as Chair of the board, Carola Lemne as vice Chair and Lars Adlersson, Rein Piir and Lena Torlegård as board members. Eva Lindgren has declined re-election. The nomination committee further proposes re-election of the auditing firm Öhrlings PriceWaterhouseCoopers as the company’s auditor. The nomination committee’s proposal is accessible, in Swedish, on the web page for the annual general meeting 2021 on www.irlab.se under the menu Corporate governance.
About Martin Nicklasson
Martin Nicklasson, born 1955, has more than 40 years of experience within Life Sciences with about 25 years in executive positions at AstraZeneca and Kabi Pharmacia, e.g. CEO Astra Pain Control AB, CEO Astra Hässle AB and member of AstraZeneca’s group management team. He has been the CEO of Biovitrum AB and Sobi AB and has an extensive experience of several boards within the Life Sciences in Sweden, Norway, Denmark, Switzerland and the UK and US.
For more information
Daniel Johnsson, Chair of the nomination committee
Phone: +46 73 687 64 00
E-mail: [email protected]
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: [email protected]
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.
Dignitana-backed insurance legislation clears Texas House, progresses to Senate
Dignitana AB,world leader in scalp cooling innovation, announces today that HB1588, a Bill mandating insurance plan coverage for scalp cooling in Texas, was passed in the Texas House of Representatives on Friday. The Bill was introduced by Rep. Jeff Leach and 4 other legislators and now moves...
AdderaCares förvärv av Linds Ortopediska godkänns av Region Stockholm
AdderaCare AB offentliggjorde den 24 mars intentionen att förvärva Linds Ortopediska AB (Linds) givet att Region Stockholm godkänner förändringen mot bakgrund av Linds ramavtal om leverans av ortopedtekniska lösningar till regionen. Region Stockholm har i dag meddelat a...
LIDDS Annual Report 2020
LIDDS AB is required to disclose this information pursuant to Nasdaq First North Growth Market – Rulebook. The information was submitted for publication, through the agency of the aforementioned contact person, on April 16, 2021 at 15:00 CET. LIDDS AB (publ) is a Swedish-based pharmaceutical compan...
Bulletin from the Annual General Meeting in Implantica AG
The general meeting adopted the annual report 2020 consisting of the statutory financial statements and the consolidated financial statements of Implantica AG for the financial year 2020 and resolved, in accordance with the board of directors’ proposal, to carry forward the net loss for the financia...